Minerva Endometrial Ablation System
Axora Medical, Inc. · Decision date Feb 12, 2026
What did the FDA decide?
FDA records P140013/S018 as a supplement to PMA P140013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.
FDA approval order statement
a supplier change for select injection molded components of the Minerva Endometrial Ablation Handpiece
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Obstetrics/Gynecology
- Decision date
- Feb 12, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140013/S018
- Regulatory pathway
- PMA supplement
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- Decision code
- OK30
- Decision date
- Feb 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, thermal ablation, endometrial.
- Applicant
- Axora Medical, Inc.
- Product code
- MNB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140013 · Original PMA
MINERVA ENDOMETRIAL ABLATION SYSTEM
P140013/S018 received
Application receipt date recorded by FDA.
P140013/S018 · FDA decision
30-Day Notice
P140013/S019 · Related supplement
MINERVA ENDOMETRIAL ABLATION SYSTEM
Timeline entries are records held by MedtechLedger for P140013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Axora Medical, Inc. | PMA approval | Jul 27, 2015 | FDA | |
MINERVA ENDOMETRIAL ABLATION SYSTEMP140013/S019 | Axora Medical, Inc. | PMA supplement | Nov 5, 2026 | FDA |
Explore the linked device profile
Other records with product code MNB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Channel Medsystems, Inc. | PMA supplement | Nov 3, 2026 | FDA | |
Cerene Cryotherapy DeviceP180032/S024 | Channel Medsystems, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Minitouch 3.8 Era System (Minitouch System)P230002/S002 | MICROCUBE, LLC | PMA supplement | Jul 13, 2026 | FDA |
Cerene Cryotherapy DeviceP180032/S023 | Channel Medsystems, Inc. | PMA supplement | Jul 8, 2026 | FDA |
Cerene Cryotherapy DeviceP180032/S022 | Channel Medsystems, Inc. | PMA supplement | Dec 18, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Axora Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1 Independent Dr. Suite 2300, Jacksonville, FL, 32202
Sources and methodology
- Original FDA record: P140013/S018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




